Videos |View More
A Comprehensive Overview of Tumor-Infiltrating Lymphocyte (TIL) Therapy for Metastatic Melanoma
Tuesday, April 9, 2024 5:30 - 6:30 PM EDT - On the heels of the FDA’s recent approval of AMTAGVI (lifileucel) for unrescectable or metastatic melanoma, join Roswell Park subject matter experts for a comprehensive provider education event.
Benefits of Combining Beta-Blocker and Checkpoint Inhibitor
The same biochemical triggers that spur a “fight or flight” response when we encounter threats may help tumor cells to thrive.
Welcome to Roswell Park | Shalana O'Brien, MD
Shalana O'Brien, MD, is a highly skilled surgical oncologist treating patients with melanoma/skin cancers, endocrine disorders and cancers, and specializing in heated chemotherapy (HIPEC) to treat advanced cancers that have spread within the abdomen.
News |View More
Can NST-628 Fill the Treatment Void For Advanced Tumors with RAS or RAF Mutations?
A phase 1 clinical trial underway at Roswell Park Comprehensive Cancer Center will evaluate the potential of a “molecular glue” to treat MAPK pathway-mutated advanced solid tumors in patients who have exhausted standard treatment options.
Congressman Kennedy Announces Over $7.7 Million for State-of-the-Art Biobank at Roswell Park
Congressman Kennedy announced $7,731,872 in funding for the Roswell Park Comprehensive Cancer Center to renovate its newly integrated biobank, the Roswell Park Biorepository, made possible through the Office of the Director of the National ...
Roswell Park Earns ‘Exceptional’ Rating from National Cancer Institute With Best-Ever Core Grant
Region’s only Comprehensive Cancer Center earns maximum rating, marking five decades of consecutive NCI support.
Clinical Trial Evaluates Smaller Surgical Margins for Stage 2 Melanoma Patients
Although most primary cutaneous melanomas are treated with surgical excision alone, current international guidelines vary on the optimal size for the surgical margins, which can range from 1 to 3 cm. based on Breslow thickness.
Using CBL0137 To Treat Patients With Advanced Extremity Melanoma or Sarcoma
A central question in oncology is how to offer efficacious treatments while minimizing toxicity. This is especially true when treating advanced sarcoma and melanoma of the extremity.
New findings could lead to better tools for the identification of at-risk individuals, earlier cancer prevention.
This site is intended for healthcare professionals